Why Is Plus Therapeutics Stock Rising After Data Presentation From Brain Tumor Trial?
Plus Therapeutics Inc's (NASDAQ: PSTV) shares are moving after presenting data from a Phase 1 ReSPECT trial evaluating Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM).